Key result
Paclitaxel and carboplatin resolve DIC in a patient with metastatic clear cell renal cell carcinoma.
Why the study?
Disseminated intravascular coagulation is a critical but rare complication of advanced clear cell renal cell carcinoma, with limited data on successful treatment approaches.
Does a paclitaxel plus carboplatin regimen resolve disseminated intravascular coagulation in a patient with metastatic clear cell renal cell carcinoma?
Case Report (n=1)
Does a paclitaxel plus carboplatin regimen resolve disseminated intravascular coagulation in a patient with metastatic clear cell renal cell carcinoma?
Systemic chemotherapy with paclitaxel and carboplatin successfully resolved DIC in a patient with metastatic clear cell renal cell carcinoma without the need for specific anti-DIC therapies.
Hypothesis-generating for paclitaxel-carboplatin in DIC with metastatic clear cell RCC; prospective validation required before any practice consideration.
BACKGROUND: Disseminated intravascular coagulation is a critical complication of advanced clear cell renal cell carcinoma, despite the rarity of the occurrence of disseminated intravascular coagulation in such tumors. The diagnosis of cancer-related disseminated intravascular coagulation is mostly based on clinical bleeding and laboratory test; available data suggest that treating the primary cancer also treats the disseminated intravascular coagulation. Among three reported cases of renal cell carcinoma-related disseminated intravascular coagulation in the literature, this is the first patient whose disseminated intravascular coagulation was successfully treated, in particular, with chemotherapy without any anti-disseminated intravascular coagulation therapies. CASE PRESENTATION: /L) without clinical bleeding. His past medical history and family history were unremarkable. An open-biopsy was performed and the definitive diagnosis was bone metastatic clear cell renal cell carcinoma based on immunohistochemistry. Two weeks after admission, the diagnosis of disseminated intravascular coagulation was confirmed according to the International Society on Thrombosis and Haemostasis. Immediately, he was treated with a paclitaxel plus carboplatin regimen and disseminated intravascular coagulation completely disappeared after one cycle of systemic chemotherapy. Until recently, 11 months subsequent to the diagnosis of disseminated intravascular coagulation, he had been being undergoing maintenance therapy for metastatic clear cell renal cell carcinoma. CONCLUSIONS: First, an early detection of overt disseminated intravascular coagulation is essential, although disseminated intravascular coagulation in cancer presents as a chronic or even subclinical process with unique thrombocytopenia. Second, making a decision of systemic chemotherapy without delay at the time of disseminated intravascular coagulation diagnosis is the key to successful cancer-related disseminated intravascular coagulation treatment.
No takes yet. Share an insight, caveat, or question.
Trinh et al. (2020) conducted a case report in Metastatic clear cell renal cell carcinoma with disseminated intravascular coagulation (n=1). Paclitaxel plus carboplatin was evaluated on Resolution of disseminated intravascular coagulation. Systemic chemotherapy with paclitaxel and carboplatin successfully resolved disseminated intravascular coagulation and achieved stable disease in a patient with metastatic clear cell renal cell carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: